CDSCO-approved GLP-1 drug classes in India
Short answer
CDSCO has approved GLP-1 receptor agonists including semaglutide, tirzepatide, liraglutide, and dulaglutide for specified indications. All are Schedule H prescription medicines. Unapproved imports and compounded products are not equivalent to regulated medicines.
Approved molecules vs brands
Regulatory approval applies to drug classes (molecules), not marketing names alone. Multiple manufacturers may produce CDSCO-approved semaglutide following patent rules. Always verify approval status on the package insert.
Schedule H prescription rules
GLP-1 RAs cannot be sold without a valid prescription from an NMC-registered doctor. Online sellers offering "no prescription" products violate Indian law and pose counterfeit risk.
March 2026 CDSCO advisory
CDSCO intensified action against unauthorized sale and surrogate advertising of GLP-1 drugs. Patient education about drug classes — not brand promotion — is the compliant approach Kesho follows.
How to verify CDSCO approval before purchase
Check package inserts for manufacturer name, batch number, expiry, and storage instructions. Cross-reference molecule names with CDSCO published approval lists. Licensed pharmacies display registration numbers. Reject products marketed as research peptides, compounded GLP-1, or imports without Indian labelling.
Approved molecules currently in the Indian market
Semaglutide, tirzepatide, liraglutide, and dulaglutide represent the main CDSCO-approved GLP-1-class options for specified diabetes and obesity indications. Availability varies by city and dose strength—call ahead before travelling to purchase. Generic semaglutide expands access when sourced from licensed manufacturers.
Penalties for illegal GLP-1 sales
Selling Schedule H medicines without prescriptions violates the Drugs and Cosmetics Act. CDSCO and state drug controllers have seized unapproved imports marketed on social media. Patients purchasing grey-market product risk counterfeit pens, degraded peptides, and legal exposure—not just wasted money.
Patient rights and pharmacist questions
You may ask pharmacists to confirm cold-chain handling, show storage logs for refrigerated injectables, and provide GST invoices. Pharmacists cannot diagnose or substitute molecules without prescriber approval. If a quote seems too good to be true, verify licensing before paying—your safety depends on regulated supply chains.
Difference between CDSCO approval and brand marketing
Approval applies to molecules for specified indications; brand advertising may highlight one manufacturer. Kesho educates on drug classes without ranking brands—consistent with CDSCO March 2026 advisory against surrogate GLP-1 promotion. Patients should verify molecule names on prescriptions match dispensed product inserts.
Import and online pharmacy red flags
Overseas warehouses shipping unlabelled pens, peptide research chemicals, or prescription-free GLP-1 violate Indian law. Customs seizures and counterfeit risk are common. Legitimate treatment uses Indian licensed pharmacies with Schedule H compliance and verifiable batch numbers.
Full CDSCO guide on Kesho
Our approved drug-class list guide walks through verification steps, molecule tables, and advisory context with primary-source links. Use this landing for orientation; the complete guide supports pre-purchase checks and doctor conversations about generic semaglutide availability.
Updating your knowledge quarterly
Generic entrants and CDSCO notices change rapidly in 2026—set calendar reminders to re-read approval lists before each refill quarter. Pharmacists may switch manufacturers when stock changes; confirm CDSCO status of new brands before accepting substitutions.
Hospital formulary versus retail access
Corporate hospitals may stock limited GLP-1 molecules on formulary while retail pharmacies carry broader generic semaglutide ranges. Compare total cost including consultation when buying hospital-only brands. Outpatient dispensary prices sometimes exceed retail—ask for written retail quotes before committing.
Telemedicine prescription rules
Teleconsultation prescriptions are valid when issued by NMC-registered practitioners following state telemedicine guidelines. Pharmacy must still verify Schedule H prescription format. Avoid platforms offering GLP-1 without clinical assessment—CDSCO targets prescription-free telehealth sellers in enforcement actions.
Package insert literacy
Read package inserts for storage temperature, in-use expiry, and approved indications in English or Hindi as provided. Insert information overrides social-media dosing rumours. Photograph inserts for teleconsultation follow-ups when travelling away from your usual pharmacy.
Whistleblowing counterfeit product
Report suspected counterfeit GLP-1 to state drug controllers and your prescribing physician. Counterfeit pens may lack active ingredient or contain contaminants—never continue injections from suspect sources to avoid wasting remaining budget on harmful product.
Keeping prescription records
Store digital copies of prescriptions, GST invoices, and batch numbers for every refill. Records help pharmacists verify continuity of care and support insurance appeals. If you switch cities, carry a one-page medicine summary from your physician listing molecule, dose, and last lab dates. Kesho does not store patient records—we provide education only.
CDSCO list updates on Kesho
Our approved drug-class guide is updated when major generic launches occur. Bookmark both this landing and the full list guide—verify molecule names match your prescription before every new pharmacy. Report suspicious products to your physician and state drug control. Never purchase if labelling omits manufacturer or batch details. Schedule H rules apply regardless of online influencer promotions or discount codes. Stay informed via our editorial policy page and methodology documentation.
Quick questions
Is CDSCO Approved GLP-1 information on Kesho medical advice?
Where is the full guide?
What is the short answer on cdsco approved glp-1?
Related guides
RegulatoryCDSCO GLP-1 Advisory Explained: What Indian Patients Should Know
Central Drugs Standard Control Organisation advisories aim to protect Indian patients from counterfeit and unapproved GLP-1 products flooding social media with promises of cheap weight-loss injections. Those warnings can sound alarming if you are legitimately trying to access therapy—but they are not aimed at patients using CDSCO-approved semaglutide from licensed chemists with valid prescriptions. Here is what CDSCO communications actually mean, which channels are high risk, and how to stay compliant while pursuing legitimate metabolic care.
Read guide →RegulatoryHow to Verify a CDSCO-Approved GLP-1 Drug in India
With generic semaglutide demand surging across Indian metros, counterfeit and degraded products circulate alongside legitimate CDSCO-approved stock. Verification is not paranoia—it is the difference between effective therapy and months of wasted money with unchanged HbA1c or weight. These step-by-step checks help Indian patients confirm medicine legitimacy before injecting, whether you use innovator pens or approved generics from licensed pharmacies.
Read guide →
India AccessCheapest GLP-1 Options in India: A Drug-Class Cost Guide
"Cheapest GLP-1" searches spike every month in India—but the answer is not a single product name. Costs differ across the GLP-1 receptor agonist drug class by molecule, formulation, dose, city, and whether you choose CDSCO-approved generics. This guide compares class-level economics so you can discuss value with your doctor, not chase unsafe discounts.
Read guide →
Medically reviewed
Dr. Ananya Mehta, MD, DM Endocrinology
Consultant Endocrinologist, India
This article has been reviewed by our medical advisory team, including endocrinologists, internal medicine specialists, and cardiologists, and is based on current scientific evidence and Indian clinical guidelines. Last reviewed: June 2026.
Last medically reviewed: Jun 15, 2026